The antisense compounds used in our studies are well suited to provide a meaningful comparison because they act by a cleaving mechanism (as does siRNA) and have a similar hybrid affinity.

The cash infusion will help fund preclinical work regarding a NanoJacket particle developed by the pair. It's designed to deliver siRNA to a cancer cell and cause cancer cell death by stopping a ...